Malignant Ascites
Also known as: Ascites, Malignant / Malignant peritoneal effusion / Malignant ascites (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB06607 | Catumaxomab | For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label]. |
| DB00421 | Spironolactone | An aldosterone receptor antagonist used to treat edema, hypertension, heart failure, and aldosteronism. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB00112 | Bevacizumab | 1 | Terminated | 1 |
| DB17378 | MVR-T3011 | 1 | Recruiting | 1 |
| DB06273 | Tocilizumab | 1 | Recruiting | 1 |
| DB12525 | Molgramostim | 1 / 2 | Not Yet Recruiting | 1 |
| DB05386 | Regramostim | 1 / 2 | Not Yet Recruiting | 1 |
| DB17451 | Serplulimab | 1 / 2 | Not Yet Recruiting | 1 |
| DB00112 | Bevacizumab | 2 | Completed | 1 |
| DB00112 | Bevacizumab | 2 | Withdrawn | 1 |
| DB06607 | Catumaxomab | 2 | Completed | 1 |
| DB04849 | Cediranib | 2 | Terminated | 1 |
| DB00515 | Cisplatin | 2 | Completed | 1 |
| DB06423 | Endostatin | 2 | Completed | 1 |
| DB00331 | Metformin | 2 | Suspended | 1 |
| DB00526 | Oxaliplatin | 2 | Recruiting | 1 |
| DB01229 | Paclitaxel | 2 | Recruiting | 1 |
| DB14765 | Rivoceranib | 2 | Unknown Status | 1 |
| DB15765 | Sintilimab | 2 | Recruiting | 1 |
| DB06607 | Catumaxomab | 2 / 3 | Completed | 1 |
| DB06607 | Catumaxomab | 3 | Completed | 1 |
| DB00860 | Prednisolone | 3 | Completed | 1 |
| DB12736 | Etanidazole | Not Available | Terminated | 1 |
| DB09035 | Nivolumab | Not Available | Enrolling by Invitation | 1 |
| DB09037 | Pembrolizumab | Not Available | Enrolling by Invitation | 1 |